Of course; what’s unique about ACH-3422 is that some sell-side analysts have hyped the monotherapy data to be presented at AASLD as some kind of pivotal moment for the HCV arena.
Moreover, you've asserted on various occasions that ACH-3422's success is a fait accompli.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.